Podium to Practice: ASH® 2025 – LEUKEMIA: ASC2ESCALATE Trial

Podium to Practice: ASH® 2025 – LEUKEMIA: ASC2ESCALATE Trial

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Speakers

Dr. Lynn Savoie

Dr. Brian Leber

Studies / Trials Discussed

ID 906 – Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

This program has been made possible through unrestricted support from Astellas and Daiichi Sankyo.

Studies/trials discussed:

ID 906 – Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)
Tagged